Transgenic carrot tap roots expressing an immunogenic F1-V fusion protein from Yersinia pestis are immunogenic in mice

Journal of Plant Physiology
Sergio Rosales-MendozaSchuyler S Korban

Abstract

Expression of the protective F1 and V antigens of Yersinia pestis, as a fusion protein, in carrot was pursued in an effort to develop an alternative vaccine production system against the serious plague disease. Transgenic carrot plants carrying the F1-V encoding gene were developed via Agrobacterium-mediated transformation. Presence, integration, and expression of the F1-V encoding gene were confirmed by polymerase chain reaction (PCR), DNA gel blot analysis, and reverse-transcriptase (RT)-PCR analyses, respectively. An ELISA assay confirmed the antigenicity of the plant-derived F1-V fusion protein. Immunogenicity was evaluated subcutaneously in mice using a soluble protein extract of freeze-dried transgenic carrot. Significant antibody levels were detected following immunization. These results demonstrated that the F1-V protein could be expressed in carrot tap roots, and that the carrot F1-V recombinant protein retained its antigenicity and immunogenicity.

References

Apr 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·F J PerlakD A Fischhoff
May 28, 1996·Proceedings of the National Academy of Sciences of the United States of America·H S MasonC J Arntzen
Feb 26, 1999·Science·D A Henderson
Feb 21, 2002·Infection and Immunity·Yidong DuAke Forsberg
Feb 22, 2002·Current Opinion in Plant Biology·Pal Maliga
Jun 20, 2002·Journal of the American College of Nutrition·Schuyler S KorbanDennis E Buetow
Jan 18, 2006·Proceedings of the National Academy of Sciences of the United States of America·Luca SantiHugh S Mason
Apr 13, 2006·Expert Review of Vaccines·Yasmin ThanavalaHugh S Mason
Nov 17, 2006·Reproduction, Nutrition, Development·Eric SolerLouis-Marie Houdebine
Feb 21, 2007·Plant Cell Reports·Sergio Rosales-MendozaAngel Gabriel Alpuche-Solís
Nov 6, 2008·Drug Discovery Today·Edward P Rybicki
Apr 10, 2009·Biotechnology Advances·Siddharth TiwariRakesh Tuli
Oct 1, 2009·Plant Molecular Biology·M Lucrecia AlvarezGuy A Cardineau
Oct 20, 2009·Trends in Plant Science·Henry DaniellStephen J Streatfield
Nov 26, 2009·Biotechnology Advances·M Lucrecia Alvarez, Guy A Cardineau
Mar 24, 2010·Journal of Plant Physiology·Joann M Lau, Schuyler S Korban

❮ Previous
Next ❯

Citations

Dec 29, 2015·Trends in Biotechnology·Sergio Rosales-MendozaBeatriz Meza
Sep 22, 2015·Plant Biotechnology Journal·Stephen J StreatfieldVidadi Yusibov
Jan 13, 2015·Molecular Biotechnology·Sergio Rosales-Mendoza, Marlene Anahí Tello-Olea
Jul 22, 2016·Plant Biotechnology Journal·Naila Shahid, Henry Daniell
Oct 28, 2016·GM Crops & Food
Jun 15, 2011·Applied Microbiology and Biotechnology·Jason A RosenzweigAshok K Chopra
Apr 21, 2011·Plant Cell Reports·Ruth Elena Soria-GuerraSergio Rosales-Mendoza
Jan 1, 2011·Animals : an Open Access Journal From MDPI·Petra C F Oyston, Diane Williamson
Aug 17, 2021·Biotechnology and Bioprocess Engineering : BBE·Siddhesh B GhagVishwas A Bapat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.